Client Portals

An Update On Vaccines 3 min read

Return to Normal in 2022

Nov 18, 2020 - John Osbon ( 5 mins to read)

John Osbon

The first case of COVID was Nov 17th 2019, exactly one year ago. Moderna announced a 94.5% effective vaccine this week. Pfizer’s vaccine is 95% effective and ready for emergency use approval by the FDA in one month. We can expect more effective vaccines from Regeneron, Johnson & Johnson, Sanofi and Roche which are nearing new stock price highs this week. Small and large companies are working together and an enormous amount of money is flowing towards long-term vaccine success. As we receive good virus news, we can expect more of the depressed sectors to recover. Markets are often both forward-looking and last-minute reactionary.

Timelines
The image below shows the timeframe for various vaccines to reach the approval stage. There are nine major vaccines in the pipeline that are expected to be ready for use throughout 2021. This is a rare moment of universal global collaboration. Tens of billions have been allocated to solving this vaccine puzzle. We may have half a dozen or more effective vaccine options within one year. One year is a fairly short time period for markets.

Vaccine effect on the economy
Widespread vaccinations in the US, which will take a year, will bolster the US economy. There’s no question that the biggest weight on all of us right now is the restrictions placed on everyday normal life due to COVID. Removing the COVID factor means many businesses should be able to function normally.

US airlines employ nearly half a million people. Restaurants employ nearly 15 million people. When the most impacted sectors are able to function without anxiety or restriction, the unemployment rate should fall fairly quickly.

Vaccine effect on stock prices
Widespread vaccination in the US should help almost all of the depressed sectors in the US. The positive vaccine news from this past week has certainly helped the depressed stocks rally, cruise lines, banks, retailers, hotels, REITs, etc. Public companies have widespread access to funding sources which has prevented the stock prices of even the hardest-hit sectors from dropping to distressed levels.

Once the recovery from COVID comes, we’ll have to face some permanent changes. Business travel may never recover to its previous high. Despite any temporary vaccine rallies, we need to take a view of the broader picture. E-commerce, the evolution of the public cloud, digitized finance, AI and data toolsets, digital advertising and content delivery as well as digital health care are the major growth trends. These sectors should have strong revenue growth and great opportunities for reinvested capital for many years following the vaccine.

Vaccine effect on the Fed
The Fed has promised to keep short-term rates at zero and continue economic aid “for as long as it takes”. We have had zero rates or near-zero rates for over a decade with an accompanying explosion in government debt levels. Fortunately, low rates mean the annual cost of that debt is manageable. In a global meeting on Tuesday, Jay Powell said we are not going back to the same economy. We’re moving forward to a different economy. He says the time for fiscal discipline is not now. In other words, massive fiscal stimulus in the trillions is urgently needed.

Scenario planning for the road ahead
Diversification allows investors to be successful even when the range of possible future outcomes is wide and unpredictable. Rotation trades do happen – this is where traders swap out their winners for the next opportunity. This creates volatility for everyone, even in the highest quality assets. Investors should be aware of their overall liquidity, the quality of their equity holdings and the role of alternative assets within their portfolio. The overall stock market trend remains up due to fiscal stimulus, 0% interest rates, continuous cycles of new innovations and progress on the virus.

With the widespread availability of COVID vaccines underway the first quarter of next year could look bright. A new president will take office in the United States by then. Major decisions on government spending, borrowing and budgeting will be well underway. It pays to plan for both conservative and positive scenarios for the vaccine, interest rates, inflation as well as changes in personal circumstances.

 

WEEKLY INSIGHTS
delivered to your inbox

DISCLAIMER

This communication may include forward-looking statements. All statements other than statements of historical fact are forward-looking statements (including words such as “believe,” “estimate,” “anticipate,” “may,” “will,” “should,” and “expect”). Although we believe that the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Various factors could cause actual results or performance to differ materially from those discussed in such forward-looking statements.”

“Historical performance is not indicative of future results. The investment return will fluctuate with market conditions.

Past performance is not indicative of any specific investment or future results. Views regarding the economy, securities markets or other specialized areas, like all predictors of future events, cannot be guaranteed to be accurate and may result in economic loss to the investor.

Investment strategies, philosophies, allocations and holdings are subject to change without prior notice.

This communication is intended to provide general information only and should not be construed as an offer of specifically tailored individualized advice.

While the Adviser believes the outside data sources cited to be credible, it has not independently verified the correctness of any of their inputs or calculations and, therefore, does not warranty the accuracy of any third-party sources or information.

Adviser does not endorse the statements, services or performance of any third-party vendor.

Unless stated otherwise, any mention of specific securities or investments is for hypothetical and illustrative purposes only. Adviser’s clients may or may not hold the securities discussed in their portfolios. Adviser makes no representations that any of the securities discussed have been or will be profitable.

Any IPO alerts are purely informational and should not be construed as recommendations to invest.

Adviser is not licensed to provide and does not provide legal, tax or accounting advice to clients. Advice of qualified counsel or accountant should be sought to address any specific situation requiring assistance from such licensed individuals.

Any case studies or hypothetical client profiles are for demonstration purposes only. They illustrate the breadth and depth of the many clients we represent at various life stages. Any similarities to actual Adviser’s clients past or present are strictly coincidental. Individual advice and results will vary based on each client’s circumstances, objectives and prevailing economic conditions.